Loading…

Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care

Background Cerebral blood volume (CBV) mapping with a dynamic susceptibility contrast (DSC) perfusion technique has become a clinical tool in diagnosing and follow‐up of brain tumors. Ferumoxytol, a long‐circulating iron oxide nanoparticle, has been tested for CBV mapping, but the optimal dose has n...

Full description

Saved in:
Bibliographic Details
Published in:Journal of magnetic resonance imaging 2018-08, Vol.48 (2), p.441-448
Main Authors: Varallyay, Csanad G., Nesbit, Eric, Horvath, Andrea, Varallyay, Peter, Fu, Rongwei, Gahramanov, Seymur, Muldoon, Leslie L., Li, Xin, Rooney, William D., Neuwelt, Edward A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4483-33346d9bcf33e5180b5547aa4a1005a6ce51698473ae8a9e0718892ebd6839523
cites cdi_FETCH-LOGICAL-c4483-33346d9bcf33e5180b5547aa4a1005a6ce51698473ae8a9e0718892ebd6839523
container_end_page 448
container_issue 2
container_start_page 441
container_title Journal of magnetic resonance imaging
container_volume 48
creator Varallyay, Csanad G.
Nesbit, Eric
Horvath, Andrea
Varallyay, Peter
Fu, Rongwei
Gahramanov, Seymur
Muldoon, Leslie L.
Li, Xin
Rooney, William D.
Neuwelt, Edward A.
description Background Cerebral blood volume (CBV) mapping with a dynamic susceptibility contrast (DSC) perfusion technique has become a clinical tool in diagnosing and follow‐up of brain tumors. Ferumoxytol, a long‐circulating iron oxide nanoparticle, has been tested for CBV mapping, but the optimal dose has not been established. Purpose To compare ferumoxytol DSC of two different doses to standard of care gadoteridol by analyzing time–intensity curves and CBV maps in normal‐appearing brain regions. Study Type Retrospective. Subjects Fifty‐four patients with various brain disorders. Field Strength/Sequence 3T MRI. DSC‐MRI was performed with 0.1 mmol/kg gadoteridol and 1 day later with ferumoxytol in doses of 1 or 2 mg/kg. Assessment Signal changes during first pass, relative CBV (rCBV) in normal‐appearing thalamus, putamen, and globus pallidus, and contrast‐to‐noise ratio (CNR) of the CBV maps were compared between gadoteridol and various doses of ferumoxytol using an automated method. To subjectively assess the quality of the CBV maps, two blinded readers also assessed visual conspicuity of the putamen. Statistical Tests Linear mixed effect model was used for statistical comparison. Results Compared to gadoteridol, 1 mg/kg ferumoxytol showed no difference in CNR (P = 0.6505), peak ΔR2*, and rCBV in the putamen (P = 0.2669, 0.0871) or in the thalamus (P = 0.517, 0.9787); 2 mg/kg ferumoxytol increased peak ΔR2* as well as the CNR (P < 0.0001), but also mildly increased rCBV in putamen and globus pallidus (P = 0.0005, 0.0012). Signal intensities during first pass remained highly above the noise level, with overlapping of 95% confidence intervals with noise only in 3 out of 162 tested regions. Compared to gadoteridol, the visual image quality showed mild improvement with 1 mg/kg (P = 0.02) and marked improvement with 2 mg/kg ferumoxytol (P < 0.0001). Data Conclusion 1 mg/kg ferumoxytol provides similar imaging results to standard gadoteridol for DSC‐MRI, and 2 mg/kg has a benefit of increased CNR, but may also result in mildly increased rCBV values. Level of Evidence: 3 Technical Efficacy: Stage 1 J. MAGN. RESON. IMAGING 2018;48:441–448.
doi_str_mv 10.1002/jmri.25943
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6034979</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2084311098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4483-33346d9bcf33e5180b5547aa4a1005a6ce51698473ae8a9e0718892ebd6839523</originalsourceid><addsrcrecordid>eNp9kU1rFTEYhYMotr268QdIwI0IU_M5k7gQ5OJHpSKIrkMmk2lzSSZjkmmdVf-6ud5a1IWrvMn7cDgnB4AnGJ1ihMjLXUjulHDJ6D1wjDkhDeGivV9nxGmDBeqOwEnOO4SQlIw_BEdEUswYFsfgZmuT7ZP2sPcxDvAq-iVYGPQ8u-kCXrtyCUeblhB_rCV66CY4rJMOzsC8ZGPn4nrnXVmhiVNJOhc42zQu2cUJfvpy9gpuY5h1crneS4S56GnQaYBxhEYn-wg8GLXP9vHtuQHf3r39uv3QnH9-f7Z9c94YxgRtKKWsHWRvRkotr5F6zlmnNdP1B7huTX1spWAd1VZoaVGHhZDE9kMrqOSEbsDrg-689MEOxu7NejUnF3RaVdRO_b2Z3KW6iFeqRZTJTlaB57cCKX5fbC4quJrfez3ZuGSFpZC8JaS63YBn_6C7uKSpxlMECUYxRnJPvThQJsWckx3vzGCk9r2qfa_qV68Vfvqn_Tv0d5EVwAfg2nm7_kdKfaytHER_AiMDsBg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2084311098</pqid></control><display><type>article</type><title>Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Varallyay, Csanad G. ; Nesbit, Eric ; Horvath, Andrea ; Varallyay, Peter ; Fu, Rongwei ; Gahramanov, Seymur ; Muldoon, Leslie L. ; Li, Xin ; Rooney, William D. ; Neuwelt, Edward A.</creator><creatorcontrib>Varallyay, Csanad G. ; Nesbit, Eric ; Horvath, Andrea ; Varallyay, Peter ; Fu, Rongwei ; Gahramanov, Seymur ; Muldoon, Leslie L. ; Li, Xin ; Rooney, William D. ; Neuwelt, Edward A.</creatorcontrib><description>Background Cerebral blood volume (CBV) mapping with a dynamic susceptibility contrast (DSC) perfusion technique has become a clinical tool in diagnosing and follow‐up of brain tumors. Ferumoxytol, a long‐circulating iron oxide nanoparticle, has been tested for CBV mapping, but the optimal dose has not been established. Purpose To compare ferumoxytol DSC of two different doses to standard of care gadoteridol by analyzing time–intensity curves and CBV maps in normal‐appearing brain regions. Study Type Retrospective. Subjects Fifty‐four patients with various brain disorders. Field Strength/Sequence 3T MRI. DSC‐MRI was performed with 0.1 mmol/kg gadoteridol and 1 day later with ferumoxytol in doses of 1 or 2 mg/kg. Assessment Signal changes during first pass, relative CBV (rCBV) in normal‐appearing thalamus, putamen, and globus pallidus, and contrast‐to‐noise ratio (CNR) of the CBV maps were compared between gadoteridol and various doses of ferumoxytol using an automated method. To subjectively assess the quality of the CBV maps, two blinded readers also assessed visual conspicuity of the putamen. Statistical Tests Linear mixed effect model was used for statistical comparison. Results Compared to gadoteridol, 1 mg/kg ferumoxytol showed no difference in CNR (P = 0.6505), peak ΔR2*, and rCBV in the putamen (P = 0.2669, 0.0871) or in the thalamus (P = 0.517, 0.9787); 2 mg/kg ferumoxytol increased peak ΔR2* as well as the CNR (P &lt; 0.0001), but also mildly increased rCBV in putamen and globus pallidus (P = 0.0005, 0.0012). Signal intensities during first pass remained highly above the noise level, with overlapping of 95% confidence intervals with noise only in 3 out of 162 tested regions. Compared to gadoteridol, the visual image quality showed mild improvement with 1 mg/kg (P = 0.02) and marked improvement with 2 mg/kg ferumoxytol (P &lt; 0.0001). Data Conclusion 1 mg/kg ferumoxytol provides similar imaging results to standard gadoteridol for DSC‐MRI, and 2 mg/kg has a benefit of increased CNR, but may also result in mildly increased rCBV values. Level of Evidence: 3 Technical Efficacy: Stage 1 J. MAGN. RESON. IMAGING 2018;48:441–448.</description><identifier>ISSN: 1053-1807</identifier><identifier>ISSN: 1522-2586</identifier><identifier>EISSN: 1522-2586</identifier><identifier>DOI: 10.1002/jmri.25943</identifier><identifier>PMID: 29314418</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Blood volume ; Brain ; Brain Mapping ; Brain tumors ; Cerebral blood flow ; cerebral blood volume ; Cerebrovascular Circulation ; Confidence intervals ; Conspicuity ; contrast agent ; Contrast Media ; dynamic susceptibility contrast ; Female ; Ferric Compounds - chemistry ; Ferrosoferric Oxide - chemistry ; ferumoxytol ; Field strength ; Gadolinium - chemistry ; Globus pallidus ; Heterocyclic Compounds - chemistry ; Humans ; Image quality ; Iron oxides ; Magnetic Resonance Imaging ; Male ; Mapping ; Mathematical models ; Medical imaging ; Metal Nanoparticles ; Middle Aged ; Nanoparticles ; Neuroimaging ; neuroradiology ; Noise ; Noise levels ; Organometallic Compounds - chemistry ; Perfusion ; Putamen ; Quality assessment ; Retrospective Studies ; Standard of care ; Statistical analysis ; Statistical tests ; Thalamus</subject><ispartof>Journal of magnetic resonance imaging, 2018-08, Vol.48 (2), p.441-448</ispartof><rights>2018 International Society for Magnetic Resonance in Medicine</rights><rights>2018 International Society for Magnetic Resonance in Medicine.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4483-33346d9bcf33e5180b5547aa4a1005a6ce51698473ae8a9e0718892ebd6839523</citedby><cites>FETCH-LOGICAL-c4483-33346d9bcf33e5180b5547aa4a1005a6ce51698473ae8a9e0718892ebd6839523</cites><orcidid>0000-0002-6679-6203</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29314418$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Varallyay, Csanad G.</creatorcontrib><creatorcontrib>Nesbit, Eric</creatorcontrib><creatorcontrib>Horvath, Andrea</creatorcontrib><creatorcontrib>Varallyay, Peter</creatorcontrib><creatorcontrib>Fu, Rongwei</creatorcontrib><creatorcontrib>Gahramanov, Seymur</creatorcontrib><creatorcontrib>Muldoon, Leslie L.</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Rooney, William D.</creatorcontrib><creatorcontrib>Neuwelt, Edward A.</creatorcontrib><title>Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care</title><title>Journal of magnetic resonance imaging</title><addtitle>J Magn Reson Imaging</addtitle><description>Background Cerebral blood volume (CBV) mapping with a dynamic susceptibility contrast (DSC) perfusion technique has become a clinical tool in diagnosing and follow‐up of brain tumors. Ferumoxytol, a long‐circulating iron oxide nanoparticle, has been tested for CBV mapping, but the optimal dose has not been established. Purpose To compare ferumoxytol DSC of two different doses to standard of care gadoteridol by analyzing time–intensity curves and CBV maps in normal‐appearing brain regions. Study Type Retrospective. Subjects Fifty‐four patients with various brain disorders. Field Strength/Sequence 3T MRI. DSC‐MRI was performed with 0.1 mmol/kg gadoteridol and 1 day later with ferumoxytol in doses of 1 or 2 mg/kg. Assessment Signal changes during first pass, relative CBV (rCBV) in normal‐appearing thalamus, putamen, and globus pallidus, and contrast‐to‐noise ratio (CNR) of the CBV maps were compared between gadoteridol and various doses of ferumoxytol using an automated method. To subjectively assess the quality of the CBV maps, two blinded readers also assessed visual conspicuity of the putamen. Statistical Tests Linear mixed effect model was used for statistical comparison. Results Compared to gadoteridol, 1 mg/kg ferumoxytol showed no difference in CNR (P = 0.6505), peak ΔR2*, and rCBV in the putamen (P = 0.2669, 0.0871) or in the thalamus (P = 0.517, 0.9787); 2 mg/kg ferumoxytol increased peak ΔR2* as well as the CNR (P &lt; 0.0001), but also mildly increased rCBV in putamen and globus pallidus (P = 0.0005, 0.0012). Signal intensities during first pass remained highly above the noise level, with overlapping of 95% confidence intervals with noise only in 3 out of 162 tested regions. Compared to gadoteridol, the visual image quality showed mild improvement with 1 mg/kg (P = 0.02) and marked improvement with 2 mg/kg ferumoxytol (P &lt; 0.0001). Data Conclusion 1 mg/kg ferumoxytol provides similar imaging results to standard gadoteridol for DSC‐MRI, and 2 mg/kg has a benefit of increased CNR, but may also result in mildly increased rCBV values. Level of Evidence: 3 Technical Efficacy: Stage 1 J. MAGN. RESON. IMAGING 2018;48:441–448.</description><subject>Adult</subject><subject>Aged</subject><subject>Blood volume</subject><subject>Brain</subject><subject>Brain Mapping</subject><subject>Brain tumors</subject><subject>Cerebral blood flow</subject><subject>cerebral blood volume</subject><subject>Cerebrovascular Circulation</subject><subject>Confidence intervals</subject><subject>Conspicuity</subject><subject>contrast agent</subject><subject>Contrast Media</subject><subject>dynamic susceptibility contrast</subject><subject>Female</subject><subject>Ferric Compounds - chemistry</subject><subject>Ferrosoferric Oxide - chemistry</subject><subject>ferumoxytol</subject><subject>Field strength</subject><subject>Gadolinium - chemistry</subject><subject>Globus pallidus</subject><subject>Heterocyclic Compounds - chemistry</subject><subject>Humans</subject><subject>Image quality</subject><subject>Iron oxides</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Mapping</subject><subject>Mathematical models</subject><subject>Medical imaging</subject><subject>Metal Nanoparticles</subject><subject>Middle Aged</subject><subject>Nanoparticles</subject><subject>Neuroimaging</subject><subject>neuroradiology</subject><subject>Noise</subject><subject>Noise levels</subject><subject>Organometallic Compounds - chemistry</subject><subject>Perfusion</subject><subject>Putamen</subject><subject>Quality assessment</subject><subject>Retrospective Studies</subject><subject>Standard of care</subject><subject>Statistical analysis</subject><subject>Statistical tests</subject><subject>Thalamus</subject><issn>1053-1807</issn><issn>1522-2586</issn><issn>1522-2586</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kU1rFTEYhYMotr268QdIwI0IU_M5k7gQ5OJHpSKIrkMmk2lzSSZjkmmdVf-6ud5a1IWrvMn7cDgnB4AnGJ1ihMjLXUjulHDJ6D1wjDkhDeGivV9nxGmDBeqOwEnOO4SQlIw_BEdEUswYFsfgZmuT7ZP2sPcxDvAq-iVYGPQ8u-kCXrtyCUeblhB_rCV66CY4rJMOzsC8ZGPn4nrnXVmhiVNJOhc42zQu2cUJfvpy9gpuY5h1crneS4S56GnQaYBxhEYn-wg8GLXP9vHtuQHf3r39uv3QnH9-f7Z9c94YxgRtKKWsHWRvRkotr5F6zlmnNdP1B7huTX1spWAd1VZoaVGHhZDE9kMrqOSEbsDrg-689MEOxu7NejUnF3RaVdRO_b2Z3KW6iFeqRZTJTlaB57cCKX5fbC4quJrfez3ZuGSFpZC8JaS63YBn_6C7uKSpxlMECUYxRnJPvThQJsWckx3vzGCk9r2qfa_qV68Vfvqn_Tv0d5EVwAfg2nm7_kdKfaytHER_AiMDsBg</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Varallyay, Csanad G.</creator><creator>Nesbit, Eric</creator><creator>Horvath, Andrea</creator><creator>Varallyay, Peter</creator><creator>Fu, Rongwei</creator><creator>Gahramanov, Seymur</creator><creator>Muldoon, Leslie L.</creator><creator>Li, Xin</creator><creator>Rooney, William D.</creator><creator>Neuwelt, Edward A.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6679-6203</orcidid></search><sort><creationdate>201808</creationdate><title>Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care</title><author>Varallyay, Csanad G. ; Nesbit, Eric ; Horvath, Andrea ; Varallyay, Peter ; Fu, Rongwei ; Gahramanov, Seymur ; Muldoon, Leslie L. ; Li, Xin ; Rooney, William D. ; Neuwelt, Edward A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4483-33346d9bcf33e5180b5547aa4a1005a6ce51698473ae8a9e0718892ebd6839523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Blood volume</topic><topic>Brain</topic><topic>Brain Mapping</topic><topic>Brain tumors</topic><topic>Cerebral blood flow</topic><topic>cerebral blood volume</topic><topic>Cerebrovascular Circulation</topic><topic>Confidence intervals</topic><topic>Conspicuity</topic><topic>contrast agent</topic><topic>Contrast Media</topic><topic>dynamic susceptibility contrast</topic><topic>Female</topic><topic>Ferric Compounds - chemistry</topic><topic>Ferrosoferric Oxide - chemistry</topic><topic>ferumoxytol</topic><topic>Field strength</topic><topic>Gadolinium - chemistry</topic><topic>Globus pallidus</topic><topic>Heterocyclic Compounds - chemistry</topic><topic>Humans</topic><topic>Image quality</topic><topic>Iron oxides</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Mapping</topic><topic>Mathematical models</topic><topic>Medical imaging</topic><topic>Metal Nanoparticles</topic><topic>Middle Aged</topic><topic>Nanoparticles</topic><topic>Neuroimaging</topic><topic>neuroradiology</topic><topic>Noise</topic><topic>Noise levels</topic><topic>Organometallic Compounds - chemistry</topic><topic>Perfusion</topic><topic>Putamen</topic><topic>Quality assessment</topic><topic>Retrospective Studies</topic><topic>Standard of care</topic><topic>Statistical analysis</topic><topic>Statistical tests</topic><topic>Thalamus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Varallyay, Csanad G.</creatorcontrib><creatorcontrib>Nesbit, Eric</creatorcontrib><creatorcontrib>Horvath, Andrea</creatorcontrib><creatorcontrib>Varallyay, Peter</creatorcontrib><creatorcontrib>Fu, Rongwei</creatorcontrib><creatorcontrib>Gahramanov, Seymur</creatorcontrib><creatorcontrib>Muldoon, Leslie L.</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Rooney, William D.</creatorcontrib><creatorcontrib>Neuwelt, Edward A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of magnetic resonance imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Varallyay, Csanad G.</au><au>Nesbit, Eric</au><au>Horvath, Andrea</au><au>Varallyay, Peter</au><au>Fu, Rongwei</au><au>Gahramanov, Seymur</au><au>Muldoon, Leslie L.</au><au>Li, Xin</au><au>Rooney, William D.</au><au>Neuwelt, Edward A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care</atitle><jtitle>Journal of magnetic resonance imaging</jtitle><addtitle>J Magn Reson Imaging</addtitle><date>2018-08</date><risdate>2018</risdate><volume>48</volume><issue>2</issue><spage>441</spage><epage>448</epage><pages>441-448</pages><issn>1053-1807</issn><issn>1522-2586</issn><eissn>1522-2586</eissn><abstract>Background Cerebral blood volume (CBV) mapping with a dynamic susceptibility contrast (DSC) perfusion technique has become a clinical tool in diagnosing and follow‐up of brain tumors. Ferumoxytol, a long‐circulating iron oxide nanoparticle, has been tested for CBV mapping, but the optimal dose has not been established. Purpose To compare ferumoxytol DSC of two different doses to standard of care gadoteridol by analyzing time–intensity curves and CBV maps in normal‐appearing brain regions. Study Type Retrospective. Subjects Fifty‐four patients with various brain disorders. Field Strength/Sequence 3T MRI. DSC‐MRI was performed with 0.1 mmol/kg gadoteridol and 1 day later with ferumoxytol in doses of 1 or 2 mg/kg. Assessment Signal changes during first pass, relative CBV (rCBV) in normal‐appearing thalamus, putamen, and globus pallidus, and contrast‐to‐noise ratio (CNR) of the CBV maps were compared between gadoteridol and various doses of ferumoxytol using an automated method. To subjectively assess the quality of the CBV maps, two blinded readers also assessed visual conspicuity of the putamen. Statistical Tests Linear mixed effect model was used for statistical comparison. Results Compared to gadoteridol, 1 mg/kg ferumoxytol showed no difference in CNR (P = 0.6505), peak ΔR2*, and rCBV in the putamen (P = 0.2669, 0.0871) or in the thalamus (P = 0.517, 0.9787); 2 mg/kg ferumoxytol increased peak ΔR2* as well as the CNR (P &lt; 0.0001), but also mildly increased rCBV in putamen and globus pallidus (P = 0.0005, 0.0012). Signal intensities during first pass remained highly above the noise level, with overlapping of 95% confidence intervals with noise only in 3 out of 162 tested regions. Compared to gadoteridol, the visual image quality showed mild improvement with 1 mg/kg (P = 0.02) and marked improvement with 2 mg/kg ferumoxytol (P &lt; 0.0001). Data Conclusion 1 mg/kg ferumoxytol provides similar imaging results to standard gadoteridol for DSC‐MRI, and 2 mg/kg has a benefit of increased CNR, but may also result in mildly increased rCBV values. Level of Evidence: 3 Technical Efficacy: Stage 1 J. MAGN. RESON. IMAGING 2018;48:441–448.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29314418</pmid><doi>10.1002/jmri.25943</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6679-6203</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1053-1807
ispartof Journal of magnetic resonance imaging, 2018-08, Vol.48 (2), p.441-448
issn 1053-1807
1522-2586
1522-2586
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6034979
source Wiley-Blackwell Read & Publish Collection
subjects Adult
Aged
Blood volume
Brain
Brain Mapping
Brain tumors
Cerebral blood flow
cerebral blood volume
Cerebrovascular Circulation
Confidence intervals
Conspicuity
contrast agent
Contrast Media
dynamic susceptibility contrast
Female
Ferric Compounds - chemistry
Ferrosoferric Oxide - chemistry
ferumoxytol
Field strength
Gadolinium - chemistry
Globus pallidus
Heterocyclic Compounds - chemistry
Humans
Image quality
Iron oxides
Magnetic Resonance Imaging
Male
Mapping
Mathematical models
Medical imaging
Metal Nanoparticles
Middle Aged
Nanoparticles
Neuroimaging
neuroradiology
Noise
Noise levels
Organometallic Compounds - chemistry
Perfusion
Putamen
Quality assessment
Retrospective Studies
Standard of care
Statistical analysis
Statistical tests
Thalamus
title Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A29%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebral%20blood%20volume%20mapping%20with%20ferumoxytol%20in%20dynamic%20susceptibility%20contrast%20perfusion%20MRI:%20Comparison%20to%20standard%20of%20care&rft.jtitle=Journal%20of%20magnetic%20resonance%20imaging&rft.au=Varallyay,%20Csanad%20G.&rft.date=2018-08&rft.volume=48&rft.issue=2&rft.spage=441&rft.epage=448&rft.pages=441-448&rft.issn=1053-1807&rft.eissn=1522-2586&rft_id=info:doi/10.1002/jmri.25943&rft_dat=%3Cproquest_pubme%3E2084311098%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4483-33346d9bcf33e5180b5547aa4a1005a6ce51698473ae8a9e0718892ebd6839523%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2084311098&rft_id=info:pmid/29314418&rfr_iscdi=true